secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001193125-23-076795
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics in-licenses Dr. Reddy's Abatacept biosimilar for COYA 302; $350K upfront, up to $22.7M milestones
--------------------------------------------------------------------------------

- Exclusive License and Supply Agreement with Dr. Reddy's for Abatacept biosimilar, effective April 1, 2023.
- Upfront payment of $350,000; potential development, regulatory and sales milestones up to ~$22.7 million.
- COYA 302 combines Coya's low-dose IL-2 (COYA 301) with the biosimilar for neurodegenerative diseases.
- Coya responsible for development; Dr. Reddy's for manufacture and supply of biosimilar.
- Agreement covers U.S., Canada, Mexico, South America, EU, UK, Japan; cross-license for COYA 301 in other territories.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312523076795/0001193125-23-076795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312523076795/d429716d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-076795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer